Federal judge suspends FDA approval of abortion drug mifepristone

Knowing that the abortion pill case is likely to cause public anger, Kacsmaryk took extraordinary steps to keep the lawsuit going: Usually, details of federal court cases have been published in publicly available case files. But in a March 10 call with lawyers, Casmarick said he would try to postpone the hearing’s announcement until the night before. but, Washington Post A day later, he learned of the phone and publicly warned him to the upcoming hearing.

At the March 15 hearing, Washington PostKacsmaryk seems to be open to the pro-abortion group’s claims that mithadone can be harmful or even deadly, and that the FDA approval process has been driven away.

“How many women die?” according to the organization’s attorney, Eric Baptist, inquired at the hearing. Lubbock Avalanche-Journal.

In fact, scientific evidence clearly shows Mifone is safe. As of 2018, FDA data showed that 24 out of 3.7 million people Death after taking mifilcits, although their death cannot be combined with the drug. The Division Law Firm, which defends the FDA, said 99.9% of mifepristone users did not show significant side effects.

Ordering drugs that ban FDA-approved, especially one that has been widely used, would be an unprecedented decision. Recognizing this, Kaxmarick asked the Baptist Church if he knew any other rulings had pulled drugs from the market. Associated Press. Baptist says no one thinks it is due to the FDA’s “stone wall” challenge to the drug.

In the “normal world” Lorie ChaitenAhead of the March 15 hearing, senior staff attorney for the ACLU Reproductive Freedom Program told Buzzfeed News that the lawsuit against the abortion group will be withdrawn from the outset. She said this is not the fact that we have entered “unknown waters.”

“What the plaintiff is asking for here is unprecedented,” Chatten said. “The court would not jump in and remove drugs from the market, especially if it is not on the market.” [23 years]. ”

Democratic-led states before arguments in the Texas case Sue the FDA In late February, the U.S. District Court in the Eastern District of Washington. The complaint mainly requires the court to order the agency to remove additional restrictions on mifepristone. However, it also sought a ruling that requires “any action is taken to remove mifesci from the market or reduce its availability”. On Friday, Magistrate Thomas Owen Rice Barack Obamait was found that the preliminary ban was in the public interest.

Rice still wrote that the national ban was “inappropriate” in this case, citing competition lawsuits in Texas.

While it is unclear how the Supreme Court will figure out the differences between the two opinions, the impact of Kaxmarick’s ruling will be considered nationwide if it is allowed to take effect.

“Even in a state where abortion is legal, if it is an unauthorized drug, it may continue to be prescribed, and of course there may be these sponsors continuing to distribute it,” Chaiten said.

David Mack and Stephanie K. Baer reported on the story.